RecruitingPhase 4NCT06444919

Capsaicin in Digital Osteoarthritis Versus Control

Capsaicin in Digital Osteoarthritis Versus Control : a Randomized Study

Sponsor

University Hospital, Clermont-Ferrand

Enrollment

120 participants

Start Date

Mar 7, 2025

Study Type

INTERVENTIONAL

Conditions

Neuropathic Pain Osteoarthritis Hand

Summary

The objective of this multicentric, randomized controlled double-blind clinical trial is to demonstrate the efficacy of transdermal application of capsaicin in patients with painful digital osteoarthritis with a neuropathic pain component. Participants will receive either a transdermal patch of capsaicin 179 mg (8%) or the control treatment (capsaicin 0.04%). Researchers will compare the intensity of pain in the fingers at day 60 in the capsaicin 8% group versus capsaicin 0.04% (control arm)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Capsaicin 179 Mg Cutaneous Patch and a drug called Capsaicine low dose 0.04 % for people with neuropathic pain and osteoarthritis hand. The study is currently recruiting participants at 4 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCapsaicin 179 Mg Cutaneous Patch

patch application for 30 minutes on the painful fingers.

DRUGCapsaicine low dose 0.04 %

patch application for 30 minutes on the painful fingers. the low-dose patch has a similar appearance to the active patch. It allows you to keep the blind, because it also causes reactions at the capsaicin application site (erythema, burning).